325 Results

People

  1. Lacouture
    Lacouture
  2. Kris
    Kris
  3. Hudis
    Hudis
  4. Motzer
    Motzer
  5. Saltz
    Saltz
  6. Seidman
    Seidman
  7. Heelan
    Heelan
  8. Kelsen
    Kelsen
  9. Ilson
    Ilson
  10. Norton
    Norton

Groups

  1. Department of Medicine (244)
  2. Solid Tumor Oncology Division (195)
  3. Survivorship Research (84)
  4. Gastrointestinal Oncology Service (57)
  5. Breast Medicine Service (46)
  6. Division of Subspecialty Medicine (45)
  7. Dermatology Service (41)
  8. Dermatology (41)
  9. Hematologic Malignancies, Division of (36)
  10. Surgery (34)
  1. "alopecia"
Formats
  1. Journal Article (301)
  2. Review (14)
  3. Conference Paper (5)
  4. Research Letter (3)
  5. Editorial (1)
  6. Guidelines (1)
Groups
  1. Department of Medicine (244)
  2. Solid Tumor Oncology Division (195)
  3. Survivorship Research (84)
  4. Gastrointestinal Oncology Service (57)
  5. Breast Medicine Service (46)
  6. Division of Subspecialty Medicine (45)

More Groups

People
  1. Mario Lacouture (38)
  2. Mark Kris (20)
  3. Clifford Hudis (15)
  4. Andrew Seidman (14)
  5. Leonard Saltz (14)
  6. Robert Motzer (14)

More People

Years
  1. 2025 (7)
  2. 2024 (20)
  3. 2023 (16)
  4. 2022 (11)
  5. 2021 (11)
  6. 2020 (14)

More Years

Publications
  1. Journal of Clinical Oncology (33)
  2. Cancer (14)
  3. Lancet Oncology (13)
  4. Clinical Cancer Research (12)
  5. Investigational New Drugs (11)
  6. Gynecologic Oncology (10)

More Publications

Publishers
  1. Elsevier Inc. (52)
  2. American Society of Clinical Oncology (35)
  3. Springer (31)
  4. Elsevier Science, Inc. (20)
  5. Wiley Blackwell (20)
  6. Oxford University Press (19)

More Publishers

Results (325)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial
    Journal Article

    Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer
    Journal Article

    Han, S. N.; Oza, A.; Colombo, N.; Oaknin, A.; Raspagliesi, F.; Wenham, R. M.; Braicu, E. I.; Jewell, A.; Makker, V.; Krell, J.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Randomized phase 2 clinical trial of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcomas
    Journal Article

    Attia, S.; Villalobos, V.; Hindi, N.; Wagner, A. J.; Chmielowski, B.; Oakley, G. J. 3rd; Peterson, P. M.; Ceccarelli, M.; Jones, R. L.; Dickson, M. A.
    Cancers (2023)

    Fulltext@MSK | Save
  • Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
    Review

    Pegram, M.; Pietras, R.; Dang, C. T.; Murthy, R.; Bachelot, T.; Janni, W.; Sharma, P.; Hamilton, E.; Saura, C.
    Therapeutic Advances in Medical Oncology (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): Phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
    Journal Article

    Rubinstein, P. G.; Moore, P. C.; Bimali, M.; Lee, J. Y.; Rudek, M. A.; Chadburn, A.; Ratner, L.; Henry, D. H.; Cesarman, E.; DeMarco, C. E.; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG Oncology/Gynecologic Oncology Group study 0283
    Journal Article

    O'Cearbhaill, R. E.; Miller, A.; Soslow, R. A.; Lankes, H. A.; DeLair, D.; Segura, S.; Chavan, S.; Zamarin, D.; DeBernardo, R.; Moore, K.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL
    Journal Article

    Ruan, J.; Moskowitz, A.; Mehta-Shah, N.; Sokol, L.; Chen, Z.; Kotlov, N.; Nos, G.; Sorokina, M.; Maksimov, V.; Sboner, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    Journal Article

    Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Oudard, S.; Negrier, S.; Szczylik, C.; Pili, R.; Bjarnason, G. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer
    Journal Article

    Yoshino, T.; Andre, T.; Kim, T. W.; Yong, W. P.; Shiu, K. K.; Jensen, B. V.; Jensen, L. H.; Punt, C. J. A.; Smith, D.; Garcia-Carbonero, R.; more...
    Cancer Science (2023)

    Fulltext@MSK | Save
  • Phase I study of a multivalent WT1 peptide vaccine (galinpepimut-S) in combination with nivolumab in patients with WT1-expressing ovarian cancer in second or third remission
    Journal Article

    Manning-Geist, B. L.; Gnjatic, S.; Aghajanian, C.; Konner, J.; Kim, S. H.; Sarasohn, D.; Soldan, K.; Tew, W. P.; Sarlis, N. J.; Zamarin, D.; more...
    Cancers (2023)

    Fulltext@MSK | Save